Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Lange

Ophthalmology Media, PA Medical Doctor

NPI 1174937775 CMS profile 767110

200 E State St Ste 105, Media, PA 19063

Open in the dashboard

General payments

$6,573

183 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Lange of Media, PA is reported in the CMS Open Payments database as having received $6,573 across 183 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $705 40
2024 General $905 37
2023 General $631 31
2022 General $3,520 42
2021 General $735 30
2020 General $51 2
2019 General $25 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Lange
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Jason Lange were reported at $705. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Jason Lange Ophthalmology median Middle half National median
2019 $25 $258 $104–$655 $163
2020 $51 $126 $45–$321 $114
2021 $735 $205 $76–$534 $132
2022 $3,520 $266 $100–$678 $149
2023 $631 $308 $117–$745 $160
2024 $905 $340 $127–$846 $164
2025 $705 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alimera Sciences, Inc. $3,297 30 payments
  2. Regeneron Healthcare Solutions, Inc. $1,014 50 payments
  3. Apellis Pharmaceuticals, Inc. $590 26 payments
  4. Genentech USA, Inc. $460 34 payments
  5. AbbVie, Inc. $253 9 payments
  6. EyePoint Pharmaceuticals US, Inc. $197 3 payments
  7. Mallinckrodt Hospital Products Inc. $196 9 payments
  8. Allergan Inc. $180 4 payments
  9. Bausch & Lomb Americas Inc. $125 7 payments
  10. Astellas Pharma US Inc $99 4 payments
  11. Other $164 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,073 182 payments
  2. Honoraria $2,500 1 payment
Products named General payments · program years 2019–2025
  1. ILUVIEN Ophthalmology $3,069 23 payments
  2. EYLEA $747 36 payments
  3. Syfovre $547 24 payments
  4. VABYSMO $424 32 payments
  5. OZURDEX $291 6 payments
  6. ILUVIEN treatment of diabetic macular edema in patients who have been previously treated with corticosteroid $274 9 payments
  7. EYLEA HD $267 14 payments
  8. YUTIQ Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye $228 7 payments
  9. YUTIQ Chronic Non-infectious Posterior Segment Uveitis $197 3 payments
  10. ACTHAR $196 9 payments
  11. Other $510 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

245

Median for Ophthalmology: 891

Drug cost

$7,811

Median for Ophthalmology: $68,233

Branded share of claims

52.2%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Bromfenac Sodium Generic 12 $2,355
Difluprednate Generic 25 $2,337
Prednisolone Acetate Generic 42 $1,497
Moxifloxacin Moxifloxacin Hcl Brand 26 $417
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 44 $383
Erythromycin Erythromycin Base Brand 21 $251
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 19 $138
Ketorolac Tromethamine Generic 12 $136
Ciprofloxacin Hcl Generic 15 $111
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 18 $110

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$1,985,727

Of which drugs: $1,506,807

Medicare patients

703

Average age 78

Services billed

45,275

434 women, 269 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 37%
Ischemic heart disease 33%
Chronic kidney disease 26%
Atrial fibrillation 20%
Cancer 19%
Osteoporosis 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept, 1 mg J0178 Office 130 1,006 $657,695
Injection, faricimab-svoa, 0.1 mg J2777 Office 51 16,140 $443,243
Injection, aflibercept hd, 1 mg J0177 Office 26 804 $211,960
Injection, pegcetacoplan, intravitreal, 1 mg J2781 Office 17 795 $92,896
Injection, bevacizumab, 10 mg J9035 Office 146 400 $22,815

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Syfovre
  • Apellis Pharmaceuticals, Inc. $176
$176 — 795
EYLEA
  • Regeneron Healthcare Solutions, Inc. $122
$122 — 1,006
ILUVIEN
  • Alimera Sciences, Inc. $114
$114 — —
VABYSMO
  • Genentech USA, Inc. $55
  • Genentech, Inc. $52
$107 — 16,140
EYLEA HD
  • Regeneron Healthcare Solutions, Inc. $94
$94 — 804

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

183 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record